Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.41M Sell
25,985
-12,252
-32% -$4.19M 0.27% 84
2026
Q1
$13.5M Sell
38,237
-958
-2% -$342K 0.41% 50
2025
Q4
$12.8M Sell
39,195
-1,765
-4% -$560K 0.38% 53
2025
Q3
$11.6M Buy
40,960
+3,590
+10% +$1.04M 0.35% 58
2025
Q2
$10.4M Buy
37,370
+344
+0.9% +$97.5K 0.36% 52
2025
Q1
$11.5M Sell
37,026
-3,410
-8% -$1.01M 0.44% 55
2024
Q4
$10.5M Buy
40,436
+81
+0.2% +$24K 0.42% 53
2024
Q3
$13M Buy
40,355
+30,741
+320% +$10.1M 0.58% 50
2024
Q2
$3M Sell
9,614
-25,144
-72% -$7.39M 0.14% 167
2024
Q1
$9.88M Buy
34,758
+13,241
+62% +$3.87M 0.48% 58
2023
Q4
$6.2M Sell
21,517
-7,699
-26% -$2.1M 0.33% 82
2023
Q3
$7.85M Buy
29,216
+1,794
+7% +$448K 0.43% 66
2023
Q2
$6.09M Buy
27,422
+401
+1% +$93K 0.32% 87
2023
Q1
$6.59M Buy
27,021
+4,486
+20% +$1.1M 0.35% 78
2022
Q4
$5.92M Buy
22,535
+2,413
+12% +$647K 0.36% 69
2022
Q3
$4.54M Buy
20,122
+9,320
+86% +$2.26M 0.31% 84
2022
Q2
$2.63M Sell
10,802
-7,716
-42% -$1.89M 0.2% 129
2022
Q1
$4.48M Sell
18,518
-3,802
-17% -$874K 0.36% 77
2021
Q4
$5.02M Buy
22,320
+7,659
+52% +$1.62M 0.4% 70
2021
Q3
$3.12M Sell
14,661
-285
-2% -$65.6K 0.25% 101
2021
Q2
$3.64M Sell
14,946
-405
-3% -$99.6K 0.3% 92
2021
Q1
$3.82M Sell
15,351
-10,631
-41% -$2.54M 0.34% 90
2020
Q4
$5.97M Sell
25,982
-1,852
-7% -$427K 0.58% 44
2020
Q3
$7.07M Buy
27,834
+3,403
+14% +$843K 0.76% 35
2020
Q2
$5.76M Buy
24,431
+1,351
+6% +$308K 0.76% 30
2020
Q1
$4.68M Buy
23,080
+6,716
+41% +$1.47M 0.76% 31
2019
Q4
$3.94M Buy
16,364
+54
+0.3% +$11.9K 0.69% 36
2019
Q3
$3.16M Buy
16,310
+3,734
+30% +$717K 0.51% 49
2019
Q2
$2.32M Buy
12,576
+6,390
+103% +$1.14M 0.37% 67
2019
Q1
$1.18M Sell
6,186
-1
-0% -$191 0.21% 119
2018
Q4
$1.2M Sell
6,187
-1,154
-16% -$225K 0.25% 82
2018
Q3
$1.52M Buy
7,341
+288
+4% +$56.8K 0.5% 57
2018
Q2
$1.3M Buy
+7,053
New +$1.25M 0.48% 62

Other funds holding AMGN

CX Institutional's AMGN Position: Q2 2026 in Review

CX Institutional reduced its Amgen (AMGN) stake by 32% in Q2 2026, selling an estimated $4.19M and leaving 25,985 shares worth $9.41M. The position accounts for 0.27% of the portfolio, ranked #84.

CX Institutional first reported a position in AMGN in Q2 2018 and has held it in 33 quarters since. The position peaked at $13.5M in Q1 2026. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • CX Institutional held 25,985 shares of Amgen worth $9.41M as of Q2 2026.
  • CX Institutional sold 12,252 Amgen shares in Q2 2026, an estimated $4.19M.
  • Amgen made up 0.27% of CX Institutional's portfolio in Q2 2026, its #84 holding.
  • CX Institutional first reported a position in Amgen in Q2 2018 and has held it in 33 quarters since.
  • CX Institutional's Amgen position peaked at $13.5M in Q1 2026.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.